Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Histogen Inc. (HSTO)

1.03   0.02 (1.98%) 12-02 16:00
Open: 1 Pre. Close: 1.01
High: 1.05 Low: 0.99
Volume: 51,350 Market Cap: 4(M)

Technical analysis

as of: 2022-12-02 4:23:31 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 1.58     One year: 1.91
Support: Support1: 0.9    Support2: 0.75
Resistance: Resistance1: 1.35    Resistance2: 1.63
Pivot: 1.04
Moving Average: MA(5): 1.02     MA(20): 1.04
MA(100): 1.73     MA(250): 3.41
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 32.3     %D(3): 24.6
RSI: RSI(14): 41.3
52-week: High: 9.6  Low: 0.17
Average Vol(K): 3-Month: 212 (K)  10-Days: 39 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HSTO ] has closed above bottom band by 40.8%. Bollinger Bands are 74.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.05 - 1.06 1.06 - 1.07
Low: 0.97 - 0.98 0.98 - 0.99
Close: 1.02 - 1.03 1.03 - 1.04

Company Description

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.

Headline News

Tue, 29 Nov 2022
13 Best Biotech Penny Stocks To Buy Now - Yahoo Finance

Tue, 22 Nov 2022
Should You Buy Histogen Inc (HSTO) Stock After it Has Fallen 15.04% in a Week? - InvestorsObserver

Wed, 16 Nov 2022
Is Histogen Inc (HSTO) Stock Worth a Buy Wednesday? - InvestorsObserver

Fri, 11 Nov 2022
Histogen: Q3 Earnings Snapshot - Lexington Herald Leader

Thu, 10 Nov 2022
Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update - Yahoo Finance

Thu, 10 Nov 2022
Histogen GAAP EPS of -$1.01 (NASDAQ:HSTO) - Seeking Alpha

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 4 (M)
Shares Float 4 (M)
% Held by Insiders 5.6 (%)
% Held by Institutions 3 (%)
Shares Short 92 (K)
Shares Short P.Month 95 (K)

Stock Financials

EPS -5.29
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.05
Profit Margin (%) -286.3
Operating Margin (%) -286.8
Return on Assets (ttm) -27.2
Return on Equity (ttm) -59.3
Qtrly Rev. Growth -99.2
Gross Profit (p.s.) -1.8
Sales Per Share 0.88
EBITDA (p.s.) -2.51
Qtrly Earnings Growth 0
Operating Cash Flow -10 (M)
Levered Free Cash Flow -7 (M)

Stock Valuations

PE Ratio -0.2
PEG Ratio -0.1
Price to Book value 0.25
Price to Sales 1.16
Price to Cash Flow -0.45

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-05-26
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.